


Showcasing research from Professor Jyotirmayee Dash's laboratory, School of Chemical Sciences, Indian Association for the Cultivation of Science (IACS), Kolkata, India.

*In situ* formation of transcriptional modulators using non-canonical DNA i-motifs

i-Motif DNA immobilized magnetic nanoparticles assemble the best binders via selection followed by *in situ* cycloaddition. The generated i-motif specific ligands modulate the transcription of cellular oncogenes.

We acknowledge Mr. Gopal Krishna Manna, IACS for his help with the preparation of the cover art.

As featured in:



See Jyotirmayee Dash *et al.*,  
*Chem. Sci.*, 2020, 11, 2058.

## EDGE ARTICLE

[View Article Online](#)  
[View Journal](#) | [View Issue](#)Cite this: *Chem. Sci.*, 2020, **11**, 2058

All publication charges for this article have been paid for by the Royal Society of Chemistry

# *In situ* formation of transcriptional modulators using non-canonical DNA i-motifs†‡

Puja Saha,<sup>a</sup> Deepanjan Panda,<sup>a</sup> Diana Müller,<sup>b</sup> Arunabha Maity,<sup>a</sup> Harald Schwalbe<sup>Id</sup><sup>b</sup> and Jyotirmayee Dash<sup>Id</sup><sup>\*a</sup>

Non-canonical DNA i-motifs and G-quadruplexes are postulated as genetic switches for the transcriptional regulation of proto-oncogenes. However, in comparison to G-quadruplexes, the therapeutic potential of i-motifs is less explored. The development of i-motif selective ligands by conventional approaches is challenging due to the structural complexity of i-motifs. The target guided synthetic (TGS) approach involving *in situ* cycloaddition could provide specific ligands for these dynamic DNA structures. Herein, we have used i-motif forming C-rich DNA and their complementary G-quadruplex forming DNA sequences of *c-MYC* and *BCL2* promoter regions as well as a control self-complementary duplex DNA sequence as the templates to generate selective ligands from a pool of reactive azide-alkyne building blocks. In our approach, thiolated DNA targets are immobilized on the surface of gold-coated iron nanoparticles to enable efficient isolation of the newly generated ligands from the solution mixture by simple magnetic decantation. The combinatorial *in situ* cycloaddition generated cell-membrane permeable triazole leads for respective DNA targets (*c-MYC* and *BCL2* i-motifs and G-quadruplexes) that selectively promote their formation. *In vitro* cellular studies reveal that the *c-MYC* i-motif and G-quadruplex leads downregulate *c-MYC* gene expression whereas the *BCL2* i-motif lead upregulates and the *BCL2* G-quadruplex lead represses *BCL2* gene expression. The TGS strategy using i-motif DNA nanotemplates represents a promising platform for the direct *in situ* formation of i-motif specific ligands for therapeutic intervention.

Received 4th September 2019  
Accepted 28th January 2020

DOI: 10.1039/d0sc00514b

[rsc.li/chemical-science](http://rsc.li/chemical-science)

## Introduction

Non-canonical DNA i-motifs have recently emerged as molecular switches that control cellular transcription of several proto-oncogenes<sup>1–3</sup> like *c-MYC*,<sup>4,5</sup> *BCL2*,<sup>6,7</sup> *PDGFR-β*,<sup>8</sup> *KRAS*,<sup>9</sup> *HRAS*<sup>10</sup>, *VEGF*<sup>11</sup>, *RET*<sup>12</sup> and *Rb*.<sup>13</sup> The tetraplex structure of an i-motif consists of two interspersed C-rich duplexes zipped together by intercalated hemiprotonated C<sup>+</sup>·C base pairing at acidic pH.<sup>14–16</sup> The pH responsive structure and reversible conformational switching properties of i-motifs have been potentially used in DNA nanotechnology.<sup>17–20</sup> However, i-motifs have been less investigated for designing ligands for therapeutics<sup>21–23</sup> as compared to complementary G-quadruplexes (G<sub>4</sub>s) that have been well studied in the past decade.<sup>24–26</sup> The reported i-motif ligands such as the cationic porphyrin TmPyP4,<sup>27</sup>

phenanthroline derivatives,<sup>28</sup> neomycin-erythrin conjugates,<sup>29</sup> crystal violet,<sup>30</sup> Thioflavin T<sup>31,32</sup> and berberine<sup>33</sup> do not show significant selectivity for i-motif structures over duplex and quadruplex structures. In subsequent years, Hurley and co-workers identified a cholestane derivative as a potent and specific i-motif binder that can provide an approach for regulating *BCL2* transcription in cancer cells.<sup>7</sup> At present, only a couple of i-motif specific ligands *e.g.*, the type II topoisomerase inhibitor mitoxantrone,<sup>34</sup> peptidomimetic ligands,<sup>35</sup> benzothienopyrene derivatives<sup>8</sup> and acridone derivatives<sup>36</sup> have been tested in the cellular system. In a recent study, Dzatko *et al.* performed state-of-the-art in-cell NMR spectroscopy to establish that i-motifs remain stable in the complex cellular environment of live mammalian cells.<sup>37</sup> Moreover, the recent breakthrough discovery of the *in vivo* existence of i-motif structures in the nuclei of human cells by Christ and Dinger's group illustrates the therapeutic potential of i-motifs.<sup>38</sup> However, the development of selective ligands for i-motifs is difficult and challenging as i-motifs share a similar four stranded structural topology with quadruplexes. We herein demonstrate target guided *in situ* cycloaddition using i-motif linked gold coated magnetic nanoparticles as templates to generate selective ligands for i-motifs over G<sub>4</sub>s and double stranded DNA (dsDNA). The target-guided synthesis (TGS) using azide-alkyne cycloaddition (*in*

<sup>a</sup>School of Chemical Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata-700032, India. E-mail: ocjd@iacs.res.in

<sup>b</sup>Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University, Max-von-Laue Strasse 7, Frankfurt, D-60438, Germany

† This work is dedicated to Professor Hans-Ulrich Reissig on the occasion of his 70<sup>th</sup> birthday.

‡ Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc00514b

*situ* click chemistry) is a powerful fragment-based drug design strategy in which the target directly templates the ligation of appropriate reactive fragments to generate high affinity target-specific compounds. This method has been elegantly used for the discovery of potent binders for protein targets.<sup>39–42</sup> In comparison, only a few nucleic acid targets are used as templates like duplex DNA,<sup>43</sup> DNA and RNA quadruplexes<sup>44,45</sup> and (CCUG)<sub>n</sub> repeat RNAs<sup>46</sup> to generate selective ligands.


In this study, we have immobilized i-motifs present in *c-MYC* and *BCL2* gene promoters on the surface of gold-coated magnetic nanoparticles (i-motif DNA nanotemplates) to enable efficient isolation and identification of selective triazole ligands from a library of azide and alkyne building blocks. In this approach, the DNA nanotemplates would capture the newly assembled triazole products that could be easily separated from the DNA templates by magnetic decantation. In addition, complementary *c-MYC* and *BCL2* G-quadruplexes as well as double stranded DNA targets have been used as control DNA templates. The binding affinity, selectivity and gene regulatory activities of triazole leads for G-quadruplexes and i-motifs have been evaluated by using different biophysical and cell-based biological assays.

## Results and discussion

### Preparation and characterization of DNA nanotemplates

Thiolated i-motif forming C-rich sequences present in the promoter regions of *c-MYC* and *BCL2* genes were grafted on the surface of gold-coated magnetic nanoparticles (Au@Fe<sub>3</sub>O<sub>4</sub>) using thiol–gold chemistry to obtain *c-MYC* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> and *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> nanotemplates (Fig. 1).

The attachment of i-motif DNAs on Au@Fe<sub>3</sub>O<sub>4</sub> NPs was confirmed by the peak at 260 nm for DNA along with the characteristic SPR peak of Au at ~550 nm in the UV-Vis spectrum in 10 mM sodium cacodylate buffer, pH 5.5 (Fig. 2a and b). TEM imaging revealed that i-motif DNA linked NPs are



**Fig. 2** Characterization of i-motif DNA linked magnetic nanoparticles (C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> NPs). (a and b) UV-Vis absorption spectra of *c-MYC* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> and *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> NPs at 25 °C; (c and d) TEM images of *c-MYC* and *BCL2* i-motif functionalized Au@Fe<sub>3</sub>O<sub>4</sub> NPs (scale bar 50 nm); (e and f) CD spectra of *c-MYC* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> and *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> NPs; buffer: 10 mM sodium cacodylate, pH 5.5.


spherical in size and 13–15 nm in diameter (Fig. 2c and d). CD spectroscopy illustrated that DNA sequences grafted on nanoparticles retain i-motif conformation by displaying a positive peak at 285 nm and a negative peak at 260 nm (Fig. 2e and f). The complementary thiolated *c-MYC* and *BCL2* G-rich sequences as well as a self-complementary dsDNA sequence were also immobilized on Au@Fe<sub>3</sub>O<sub>4</sub> NPs to prepare G<sub>4</sub> and dsDNA nanotemplates.

### Design and synthesis of clickable building blocks

To perform metal free azide–alkyne cycloaddition using DNA nanotemplates, we developed a library of four water-soluble alkynes (**1a–d**) and seventeen azides (**2a–q**) containing different functional groups (Fig. 3). Two carbazole derived alkynes, containing an aryl carboxamide motif (**1a**)<sup>45</sup> and a pyrrolidine motif (**1b**), an indole alkyne (**1c**) containing a pyrrolidine motif and a morpholino substituted benzamide alkyne derivative (**1d**) were prepared. The heteroaromatic ring system of alkynes could interact with DNA through  $\pi$ -stacking and their protonable amine side chains could participate in electrostatic interactions with the DNA sugar-phosphate backbone. The azide library consists of aliphatic and aromatic azides that include a range of functional groups such as amines (**2a**, **2b**, **2e**, **2h**, and **2n**), alcohols (**2c** and **2g**), carboxylic acids (**2d** and **2j**), an aldehyde (**2i**), an ester (**2k**), a nitro (**2l**), a simple phenyl azide (**2f**), *meta*- and *para*-substituted carboxamides (**2o** and **2p**), an amino acid (**2m**) and a nucleoside (**2q**). These functional groups could promote hydrogen bonding, electrostatic or base stacking interactions with DNA targets. As shown in Fig. 3, the combinations of these azide and alkyne building blocks could provide 136 possible regioisomers that include both *anti*(1,4)- and *syn*(1,5)-triazoles. In the presence of a target, the *in situ* cycloaddition generally provides triazole products that effectively bind to the target *via* non-covalent interactions.

### Lead discovery by DNA nanotemplated reactions

Each alkyne fragment (1  $\mu$ M) was separately mixed with the azide library (4  $\mu$ M of each azide fragment) in the presence of



**Fig. 1** DNA functionalized nanotemplates; i-motifs (*c-MYC* and *BCL2*), G-quadruplexes (*c-MYC* and *BCL2*), double and C-rich single stranded DNA (dsDNA and ssDNA) functionalized gold coated magnetic nanoparticles.








Fig. 3 Alkyne (1a–d) and azide (2a–q) fragments and regioisomeric 1,4-*anti* (3aa–3dq) and 1,5-*syn* (3aa–3dq) triazoles derived from combinations of alkyne and azide building blocks.

C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> DNA nanotemplates (10 μL) in 10 mM sodium cacodylate buffer, pH 5.5 at rt (Fig. 4). The reaction vials were continuously mixed for 4 days and the newly ligated triazole products along with i-motif nanotemplates were separated from the unreacted fragments by washing with buffer followed by magnetic decantation. The triazole products were then separated from the nanotemplates by adding 1 M LiCl and heating the mixture at 65 °C in sodium cacodylate buffer (pH 5.5), followed by instant magnetic separation of the DNA nanotemplates. The combination of LiCl and heat destabilizes i-

motifs<sup>47</sup> and releases the bound triazole products from the DNA. The collected supernatants containing the products were characterized by HPLC-MS analysis. Control experiments were carried out using the same chemical library in the presence of *c-MYC* and *BCL2* G<sub>4</sub> and dsDNA nanotemplates in 100 mM Tris-KCl buffer (pH 7.4).

The HPLC and MS analysis revealed that in the presence of *c-MYC* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>, alkyne 1a afforded three triazole hits, 3ab (cycloadduct of 1a and 2b), 3ae (cycloadduct of 1a and 2e), and 3an (cycloadduct of 1a and 2n) in a ratio of 49 : 20 : 31 (Fig. 5a, c





Fig. 4 Schematic representation of the target guided synthetic approach using i-motif magnetic nanotemplates (*c-MYC* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> & *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>) for *in situ* formation of potent binders.

(a) *c*-MYC C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>

Alkynes	Azide counterpart of Hit ligands		
<b>1a</b>	<b>2e</b> F-1	<b>2b</b> F-2	<b>2n</b> F-3
<b>1b</b>	<b>2e</b> F-1	<b>2n</b> F-2	<b>2o</b> F-3
<b>1c</b>	No hits		
<b>1d</b>	No hits		

(b) *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>

Alkynes	Azide counterpart of Hit ligands	
<b>1a</b>	No hits	
<b>1b</b>	<b>2m</b> F-1	<b>2n</b> F-2
<b>1c</b>	No hits	
<b>1d</b>	No hits	





(c) *c*-MYC C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> with Alkyne **1a**(d) *c*-MYC C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> with Alkyne **1b**(e) *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> with Alkyne **1b**

Fig. 5 The hit compounds formed using (a) *c*-MYC and (b) *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> templates. The selective lead compounds are highlighted. HPLC chromatograms of the products obtained (c and d) with *c*-MYC C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> and (e) with *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>.

and S5a, ESI<sup>+</sup>); alkyne **1b** provided **3be**, **3bn** and **3bo** (15 : 56 : 29) (Fig. 5a, d and S5b, ESI<sup>+</sup>); no hit products were obtained from alkynes **1c** and **1d** (Fig. 5a). In the presence of *BCL2* C<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>, only alkyne **1b** afforded triazole products **3bm** and **3bn** in a ratio of 18 : 82 whereas no hit compounds were detected from alkynes **1a**, **1c** and **1d** (Fig. 5b, e and S5c, ESI<sup>+</sup>).








In the control experiment with *c*-MYC G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>, three hits (**3ab**, **3ae**, and **3ao** in a 13 : 9 : 78 ratio) were obtained from alkyne **1a** and no product was obtained from alkynes **1b–d** (Fig. 6a and S5c, ESI<sup>+</sup>). The cycloaddition of azide–alkyne fragments in the presence of *BCL2* G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> produced a single hit **3ap**, derived from **1a** and **2p** (Fig. 6b and S5d<sup>†</sup>). The

*dsDNA* nanotemplate provided 3 hits (**3ab**, **3ae** and **3an** in a ratio of 13 : 29 : 58) from alkyne **1a** and 2 hits (**3bn** and **3bo** in a 45 : 55 ratio) from alkyne **1b** (Fig. S5f, g and S6<sup>†</sup>). In addition, control experiments carried out with single-stranded *c*-MYC and *BCL2* C-rich DNA sequences (ssDNA·Au@Fe<sub>3</sub>O<sub>4</sub>) immobilized on the nanoparticle surface (pH 7.4) showed no peaks in the HPLC chromatogram, indicating that C-rich ssDNA could not select the azide–alkyne fragments and promote the cycloaddition to generate any triazole product.






As azide fragments **2o** and **2p** are positional isomers having identical molecular mass, the formation of **3bo**, **3ao** and **3ap** was confirmed by performing separate templated cycloaddition




(a) *c*-MYC G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>

Alkynes	Azide counterpart of Hit ligands
	 2e
	 2o
	 2b
	

(b) *BCL2* G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub>

Alkynes	Azide counterpart of Hit ligands
	 2p
	
	
	

Fig. 6 The hit compounds formed using (a) *c*-MYC and (b) *BCL2* G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> templates. The selective lead compounds are highlighted.

of the corresponding alkynes with the azides **2o** or **2p** in the presence of the respective DNA nanotemplates. The *c*-MYC G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> and dsDNA·Au@Fe<sub>3</sub>O<sub>4</sub> produced **3bo** derived from **1b** and **2o** but no product was formed from **1b** and **2p**. By performing a similar set of cycloadditions, we observed that the *c*-MYC and *BCL2* G<sub>4</sub>·Au@Fe<sub>3</sub>O<sub>4</sub> promoted the formation of **3ao** and **3ap** from azides **2o** and **2p**, respectively.

The comparison of hit products generated by using different DNA nanotemplates reveals that ligands **3be** and **3bm**, obtained using *c*-MYC and *BCL2* i-motifs, respectively, are selective leads for i-motifs, and ligands **3ao** and **3ap** are selective for *c*-MYC and *BCL2* G<sub>4</sub>s, respectively. The other hit compounds are considered non-specific as they were obtained using more than one DNA template.


### Determination of the *syn/anti* selectivity of triazole leads

In order to determine the regiochemistry of selective triazole leads **3be**, **3bm**, **3ao** and **3ap**, the cycloaddition of their corresponding azide and alkyne fragments was carried out under thermal and Cu(I)-catalyzed conditions (Fig. S2–S4†). A mixture of both *anti* (1,4)- and *syn* (1,5)-triazole regioisomers was obtained by thermal cycloaddition, and regioisomerically pure 1,4-disubstituted triazole products were formed by the Cu(I)-assisted reaction. The comparison of the HPLC retention times of the DNA-templated reaction mixture with those of the triazole products obtained *via* thermal and Cu(I)-catalyzed cycloaddition (Fig. S7–S10†) revealed that the DNA nanotemplates promote the cycloaddition of proximally oriented azide and alkyne fragments in a regioselective manner by preferentially generating *anti* (1,4)-triazole regioisomers for the DNA targets (Fig. 7).

The yields of lead *anti*-triazoles were determined by performing time dependent cycloaddition of corresponding alkyne (**1a** and **1b**) and azide (**2e**, **2m**, **2o** and **2p**) fragments in the presence of DNA nanotemplates. Alkyne **1b** reacted with azide **2e** in the presence of the *c*-MYC i-motif nanotemplate to form *anti*-**3be** in 48% yield. Similarly, leads *anti*-**3bm** (from **1b** and **2m** by using the *BCL2* i-motif), *anti*-**3ao** (from **1a** and **2o** using the *c*-MYC G-quadruplex) and *anti*-**3ap** (from **1a** and **2p** by using the *BCL2* quadruplex) were obtained in 60%, 44% and 56% relative yields, respectively (Fig. S11–S14, ESI†).

### Binding affinity and specificity of triazole leads for DNA targets

FRET-based DNA melting studies<sup>48,49</sup> using dual labelled *c*-MYC and *BCL2* i-motifs and G<sub>4</sub> DNA and dsDNA sequences revealed

Fig. 7 Triazole leads formed *via in situ* cycloaddition promoted by DNA nanotemplates.

that ligand **3be**, formed by using *c*-MYC  $C_4$ ·Au@Fe<sub>3</sub>O<sub>4</sub>, showed a comparatively high preference for *c*-MYC i-motifs, exhibiting a  $\Delta T_m$  value of 29.7 °C at 1  $\mu$ M concentration (Table 1, Fig. S15<sup>†</sup>). The *BCL2* i-motif lead **3bm** shows a comparatively high  $\Delta T_m$  value (18.6 °C at 1  $\mu$ M) for the *BCL2* i-motif over other DNA structures. Ligand **3ao**, generated using the *c*-MYC  $G_4$ ·Au@Fe<sub>3</sub>O<sub>4</sub> nanotemplate, is found to exhibit high stabilization towards *c*-MYC  $G_4$  ( $\Delta T_m$  = 19.3 °C at 1  $\mu$ M) and **3ap** exhibits a relatively high  $\Delta T_m$  value (11.8 °C at 1  $\mu$ M) for *BCL2*  $G_4$  over other investigated DNAs. In addition, these triazole leads exhibit a weak stabilization potential for dsDNA illustrating their selectivity for four stranded structures over duplex DNA.

The binding selectivity of lead ligands was further validated by fluorescence spectroscopic titrations (Fig. 8 and S16<sup>†</sup>, Table

**Table 1** Stabilization potentials ( $\Delta T_m$ ) and apparent dissociation constants [ $K_{d(app)}$ ] of lead triazole ligands for i-motif ( $C_4$ ), G-quadruplex ( $G_4$ ) and dsDNA as determined by the FRET based DNA melting assay and fluorescence spectroscopic titrations<sup>f</sup>


	$\Delta T_m$ (°C) at 1 $\mu$ M ligand concentration				$K_{d(app)}$ ( $\mu$ M)			
	<b>3be</b>	<b>3bm</b>	<b>3ao</b>	<b>3ap</b>	<b>3be</b>	<b>3bm</b>	<b>3ao</b>	<b>3ap</b>
<sup>a</sup> <i>c</i> -MYC $C_4$	29.7	2.9	6.4	2.1	0.25	ns	1.61	1.83
<sup>b</sup> <i>BCL2</i> $C_4$	12.7	18.6	3.5	0.4	1.18	0.66	1.63	2.01
<sup>c</sup> <i>c</i> -MYC $G_4$	3.7	1.6	19.3	5.7	1.59	ns	0.17	1.62
<sup>d</sup> <i>BCL2</i> $G_4$	1.8	1	7.7	11.8	2.21	ns	0.91	0.68
<sup>e</sup> dsDNA	0.2	0.6	0.9	0.5	ns	ns	ns	ns

<sup>a</sup>  $T_m$  for *c*-MYC  $C_4$ , 47.2 °C. <sup>b</sup>  $T_m$  for *BCL2*  $C_4$ , 44.0 °C. <sup>c</sup>  $T_m$  for *c*-MYC  $G_4$ , 68.3 °C. <sup>d</sup>  $T_m$  for *BCL2*  $G_4$ , 72.1 °C. <sup>e</sup>  $T_m$  for dsDNA, 63.4 °C. Buffer used for FRET melting studies; i-motif ( $C_4$ ) DNA: 10 mM sodium cacodylate buffer (pH 5.5), G-quadruplex ( $G_4$ ) and dsDNA: 60 mM potassium cacodylate buffer (pH 7.4). <sup>f</sup> ns:  $K_{d(app)}$  could not be determined due to non-significant changes in fluorescence intensity upon addition of DNA. Experiments were performed in triplicate and the average values are provided.

1).<sup>50–54</sup> As shown in Fig. 8, ligand **3be** exhibited a binding preference for the *c*-MYC i-motif showing ~5-fold fluorescence quenching<sup>50,51</sup> upon titration with *c*-MYC i-motif DNA. The fluorescence intensity of **3be** was quenched by only ~2-fold by the *BCL2* i-motif and quadruplexes (*c*-MYC and *BCL2*). Moreover, this ligand showed negligible changes in the fluorescence intensity upon addition of dsDNA (Fig. S16<sup>†</sup>).

Ligand **3bm**, generated solely by using *BCL2*  $C_4$ ·Au@Fe<sub>3</sub>O<sub>4</sub>, showed ~2.0 fold fluorescence quenching along with a 20 nm blue shift in the presence of the *BCL2* i-motif, while it showed negligible fluorescence changes with other DNA targets (Fig. S16<sup>†</sup>). The observed quenching phenomenon for **3be** and **3bm** with i-motifs may be attributed to the possibility of resonance energy transfer between the DNA-bases and ligand which needs strong interactions between the molecules.<sup>52</sup> The fluorescence intensity of ligand **3ao** was enhanced 4-fold with a blue shift of 33 nm in the presence of *c*-MYC quadruplex DNA (Fig. S16<sup>†</sup>) whereas a 2–2.5 fold enhancement was observed with other quadruplexes and i-motifs. A 5-fold fluorescence enhancement for **3ap** was observed with a 15 nm red shift in the presence of *BCL2* quadruplex DNA, whereas relatively lower fluorescence enhancement (3–3.5 fold) was obtained with other DNAs (Fig. S16<sup>†</sup>). The significant fluorescence enhancement observed for compounds **3ao** and **3ap** indicated their binding with the hydrophobic sites of the  $G_4$ -DNA by stacking interactions.<sup>53,54</sup>

The apparent dissociation constants [ $K_{d(app)}$ ] determined from fluorimetric titrations revealed that ligand **3be** binds the *c*-MYC i-motif with an apparent  $K_d$  value of 0.25  $\mu$ M, which is 5–9 fold higher than the  $K_d$  values determined for other investigated i-motif and  $G_4$ -DNA targets. Triazole **3bm** binds the *BCL2* i-motif with a dissociation constant ( $K_d$ ) of 0.66  $\mu$ M while showing no significant fluorescence response with other DNAs. The affinity of **3ao** for *c*-MYC  $G_4$  ( $K_d$  = 0.17  $\mu$ M) is about 5–10 fold higher than that for i-motifs and *BCL2*  $G_4$ -DNA. Ligand **3ap**



**Fig. 8** (a–d) Fluorescence spectroscopic titrations of lead ligands (1  $\mu$ M) with *c*-MYC  $C_4$ , *BCL2*  $C_4$ , *c*-MYC  $G_4$  and *BCL2*  $G_4$  DNA. (e–h) Fluorescence response curves of **3be**, **3bm**, **3ao** and **3ap** with incremental addition of *c*-MYC  $C_4$  (blue), *BCL2*  $C_4$  (orange), *c*-MYC  $G_4$  (purple), *BCL2*  $G_4$  (green) and dsDNA (light blue).



also showed higher binding affinity for *BCL2* G<sub>4</sub>-DNA ( $K_d = 0.68 \mu\text{M}$ ) in comparison to other DNA targets (Table 1).

Next, we performed a competitive binding assay<sup>55</sup> using the DNA nanotemplates to further verify the selectivity of the lead compounds. The triazole leads (**3be**, **3bm**, **3ao** and **3ap**) were mixed in an equimolar concentration (each ligand concentration is 5  $\mu\text{M}$ ) and incubated with each i-motif and G-quadruplex nanotemplate ( $\text{C}_4\cdot\text{Au@Fe}_3\text{O}_4$  and  $\text{G}_4\cdot\text{Au@Fe}_3\text{O}_4$ ) separately for 30 min at room temperature under continuous stirring. The underlying principle of the assay is to select the structure-selective ligands using the DNA template from the mixture of lead triazole ligands and thus the captured ligand can be considered a specific and selective ligand for the respective DNA target. After incubation, the template-bound ligands were isolated from the template as per the protocol used in TGS and identified by HPLC and MS-analysis. The competitive binding experiments show that the *c-MYC*  $\text{C}_4\cdot\text{Au@Fe}_3\text{O}_4$  nanotemplate selected only **3be** from the mixture of four triazoles (Fig. S17a†). Interestingly, as expected, the experiments carried out with the other three DNA nanotemplates showed a single peak in the HPLC chromatogram that corresponds to ligands **3bm**, **3ao** and **3ap** for *BCL2*  $\text{C}_4\cdot\text{Au@Fe}_3\text{O}_4$ , *c-MYC*  $\text{G}_4\cdot\text{Au@Fe}_3\text{O}_4$  and *BCL2*  $\text{G}_4\cdot\text{Au@Fe}_3\text{O}_4$ , respectively (Fig. S17b–d†). These results further confirm that the triazole leads obtained by TGS are specific to their respective DNA that drives their formation from their corresponding azide and alkyne fragments.

1D <sup>1</sup>H NMR titration further revealed that incremental addition of ligand **3be** to the *c-MYC* i-motif results in general line broadening of the characteristic imino signals (15–16 ppm) for C–C<sup>+</sup> base pairs (Fig. S18a, ESI†). Furthermore, it induces significant line broadening in the aromatic region of the *c-MYC* i-motif (Fig. S18b†), indicating that **3be** interacts with the *c-MYC* i-motif. In the absence of the ligand, NMR signals of the *BCL2* i-motif are broadened due to intermediate chemical exchange showing conformational dynamics of the DNA alone. Thus, no observable changes are found with addition of **3bm**. 1D NMR titrations further revealed that ligand **3ao** strongly interacts with *c-MYC* G<sub>4</sub> (Fig. S18g–i†) showing significant line broadening suggesting binding in intermediate exchange on NMR time scale. In the case of **3ap**, general line broadening of the imino and aromatic signals of *BCL2* G<sub>4</sub> in a 3 : 1 ligand/DNA molar ratio was observed indicating binding with a  $K_d$  in the high micro molar regime (Fig. S18j–l†). CD spectroscopic titrations confirmed that these ligands retain the topology of these four stranded DNA targets (Fig. S19, ESI†).

The results reveal that the  $\Delta T_m$  values and  $K_d$  values of triazole leads for DNA targets obtained from FRET melting and fluorescence spectroscopic titrations are in good agreement with each other. These results are consistent with the results obtained by TGS, indicating that a triazole lead shows selectivity for the DNA target that promotes its formation. For instance, **3be** obtained using the *c-MYC* i-motif shows a high stabilization potential and high binding affinity for the *c-MYC* i-motif compared to other DNA targets. In summary, ligands **3be** and **3ao** displayed high affinity and specificity for the *c-MYC* i-motif and G-quadruplex DNA, respectively. In contrast, ligand **3bm** and **3ap** exhibited modest binding affinity for the *BCL2* i-motif

and *BCL2* G-quadruplex DNA, respectively, but maintained considerable specificity for their respective DNA targets in comparison to other investigated DNA targets.

### In vitro biological activity of triazole leads

The cytotoxicity of lead compounds was next evaluated in a human cervical cancer cell line (HeLa), a small lung adenocarcinoma cell line (A549), the *BCL2* overexpressing EBV infected marmoset cell line B95.8 and the human normal kidney epithelial cell line NKE. It was observed that **3be**, **3ao** and **3ap** inhibit cell proliferation in all the tested cancer cells (HeLa, A549 and B95.8) while they show minimal cytotoxicity towards the NKE cell line. The *BCL2* i-motif lead **3bm** is non-toxic to both normal and cancer cell lines (Table 2 and Fig. S20†). The cellular localization of these triazole leads was then monitored in HeLa cells by confocal microscopy. It was observed that ligand **3ao** (*c-MYC* G-quadruplex lead) exclusively localizes in the cell nucleus, and ligands **3be**, **3bm** and **3ap** penetrate into the cell cytoplasm and the cell nucleus. This suggests that these triazole leads are able to translocate into the cell nucleus (Fig. S21, ESI†). The ability of these ligands to induce apoptosis in cancer cells was further evaluated by annexin V/PI double staining FACS analysis. FACS analysis indicated that ligands **3be**, **3ao** and **3ap** induced significant apoptotic cell death in HeLa cells in a dose-dependent manner (Fig. S22†). In comparison, the *BCL2* i-motif lead **3bm** did not induce apoptosis in HeLa cells at 2 and 4  $\mu\text{M}$  concentrations.

The qRT-PCR and western blotting results showed that the *c-MYC* i-motif and G<sub>4</sub> leads **3be** and **3ao** significantly reduce *c-MYC* expression at both the transcriptional and translational levels in HeLa and B95.8 cell lines (Fig. 9a, d and S23†). However, these ligands (**3be** and **3ao**) could not considerably suppress *BCL2* gene expression in cancer cells. The *BCL2* G-quadruplex ligand **3ap** inhibits the transcription and translation of the *BCL2* gene while the *BCL2* i-motif lead **3bm** up-regulates *BCL2* gene expression in both cancer cell lines (Fig. 9a, d and S23†). In addition, it was observed that ligands **3bm** and **3ap** could not alter the *c-MYC* gene expression.

Dual luciferase promoter assays further illustrated that ligands **3be** and **3ao** selectively interact with the *c-MYC* G.C rich promoter region as the ligands could repress the firefly luciferase activity of the *c-MYC* promoter luciferase construct while


Table 2 IC<sub>50</sub> values of lead compounds in human cancer cells and normal cells as measured using the XTT assay after 24 h of treatment<sup>a</sup>

IC <sub>50</sub> ( $\mu\text{M}$ )				
Ligands	HeLa	A549	B95.8	NKE
<b>3be</b>	1.0	4.2	4.5	13.6
<b>3bm</b>	>50.0	>20.0	>50.0	>25.0
<b>3ao</b>	1.9	3.0	4.9	25.0
<b>3ap</b>	7.9	14.9	8.9	>25.0

<sup>a</sup> Three individual experiments were performed and the average values are presented.








**Fig. 9** (a–d) qRT-PCR and western blotting analysis results of *c-MYC* and *BCL2* gene expression in HeLa and B95.8 cells after 24 h of treatment with **3be**, **3bm**, **3ao** and **3ap**. The *in vitro* dual luciferase promoter assay for evaluating the effect of the lead ligands on the promoter activity of (e) the *c-MYC*-FLuc promoter and (f) *BCL2*-FLuc promoter [*p* value is < 0.05].

having a negligible effect on the transcriptional activity of the *BCL2* promoter construct and normal B-DNA-containing luciferase construct (Fig. 9e, f and S24†). The *BCL2* i-motif binding ligand **3bm** upregulates the transcriptional activity of the *BCL2* promoter construct and has negligible effects on the expression levels of two other plasmid constructs. The *BCL2* G-quadruplex lead **3ap** could specifically inhibit the transcriptional activity of the *BCL2* luciferase construct. These results establish that leads obtained by *in situ* cycloaddition can modulate *c-MYC* and *BCL2* gene expression by interacting with G.C-rich promoter regions (Fig. 10).



**Fig. 10** Proposed model for targeting four-stranded DNA secondary structures within the *c-MYC* and *BCL2* gene promoter regions.

## Conclusions

This study illustrates that i-motif DNA nanotemplates, *i.e.*, gold coated magnetic nanoparticles functionalized with *c-MYC* and *BCL2* i-motifs, promote the metal-free synthesis of i-motif specific ligands. In order to generate selective ligands for i-motifs over G-quadruplex and duplex DNAs, complementary *c-MYC* and *BCL2* G-quadruplex DNA functionalized nanotemplates and a self-complementary duplex DNA functionalized nanotemplate are used as control templates. These nanotemplates generated multiple triazole hits, but triazoles selectively formed by using a particular i-motif DNA nanotemplate are considered i-motif leads. The *anti*-triazole “lead” compounds **3be** and **3bm** generated using *c-MYC* and *BCL2* i-motifs, respectively, show high specificity for their targets as evidenced by FRET-melting, fluorescence titrations and competitive binding experiments. The control G-quadruplex nanotemplates also generated **3ao** and **3ap** as the lead compounds for *c-MYC* and *BCL2* DNA quadruplexes, respectively. The lead compounds **3bm** and **3ap** obtained using the *BCL2* i-motif and G-quadruplex, though they show moderate affinity, exhibit high specificity for their respective DNA targets. Furthermore, cell-based biological assays reveal that these leads can modulate the transcription of *c-MYC* and *BCL2* genes. The *c-MYC* i-motif and G-quadruplex leads **3be** and **3ao** significantly reduce the *c-MYC* expression without affecting the *BCL2* expression. The *BCL2* G-quadruplex lead **3ap** downregulates *BCL2* gene expression while the *BCL2* i-motif lead **3bm** upregulates the expression of the *BCL2* gene by directly stabilizing the G-C rich non-canonical DNA structures. Thus, the TGS approach using DNA nanotemplates facilitates cost-effective and rapid synthesis of highly potent and selective drug candidates for biomolecular targets. Based on the binding characteristics of the lead compounds, we are currently diversifying our chemical library to expand this strategy for the development of more promising drug candidates that may display high binding affinity and specificity for the targets of interest. Furthermore, the underlying principles of the observed transcriptional alterations imposed by the lead compounds are currently under investigation.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

JD thanks Wellcome Trust-DBT India Alliance [Grant Number, IA/S/18/2/503986] for funding. The authors thank Professor Shankar Balasubramanian for useful suggestions. J. D. thanks DST for a Swarnajayanti fellowship and A. M. thanks DST for INSPIRE fellowships. The work was supported by DFG: CRC902 and by iNEXT, project number 653706, funded by the Horizon 2020 program of the European Union. Work at BMRZ is supported by the state of Hesse.



## References

- 1 T. A. Brooks, S. Kendrick and L. Hurley, *FEBS J.*, 2010, **277**, 3459–3469.
- 2 S. Kendrick and L. H. Hurley, *Pure Appl. Chem.*, 2010, **82**, 1609–1621.
- 3 E. P. Wright, J. L. Huppert and Z. A. E. Waller, *Nucleic Acids Res.*, 2017, **45**, 2951–2959.
- 4 J. X. Dai, E. Hatzakis, L. H. Hurley and D. Z. Yang, *PLoS One*, 2010, **5**, e11647.
- 5 C. Sutherland, Y. X. Cui, H. B. Mao and L. H. Hurley, *J. Am. Chem. Soc.*, 2016, **138**, 14138–14151.
- 6 S. Kendrick, Y. Akiyama, S. M. Hecht and L. H. Hurley, *J. Am. Chem. Soc.*, 2009, **131**, 17667–17676.
- 7 S. Kendrick, H. J. Kang, M. P. Alam, M. M. Madathil, P. Agrawal, V. Gokhale, D. Z. Yang, S. M. Hecht and L. H. Hurley, *J. Am. Chem. Soc.*, 2014, **136**, 4161–4171.
- 8 R. V. Brown, T. Wang, V. R. Chappeta, G. H. Wu, B. Onel, R. Chawla, H. Quijada, S. M. Camp, E. T. Chiang, Q. R. Lassiter, C. Lee, S. Phanse, M. A. Tumidge, P. Zhao, J. G. N. Garcia, V. Gokhale, D. Z. Yang and L. H. Hurley, *J. Am. Chem. Soc.*, 2017, **139**, 7456–7475.
- 9 C. E. Kaiser, N. A. Van Ert, P. Agrawal, R. Chawla, D. Z. Yang and L. H. Hurley, *J. Am. Chem. Soc.*, 2017, **139**, 8522–8536.
- 10 G. Miglietta, S. Cogoi, E. B. Pedersen and L. E. Xodo, *Sci. Rep.*, 2015, **5**, 18097.
- 11 K. Guo, V. Gokhale, L. H. Hurley and D. Sun, *Nucleic Acids Res.*, 2008, **36**, 4598–4608.
- 12 K. Guo, A. Pourpak, K. Beetz-Rogers, V. Gokhale, D. Sun and L. H. Hurley, *J. Am. Chem. Soc.*, 2007, **129**, 10220–10228.
- 13 Y. Xu and H. Sugiyama, *Nucleic Acids Res.*, 2006, **34**, 949–954.
- 14 K. Gehring, J. L. Leroy and M. Gueron, *Nature*, 1993, **363**, 561–565.
- 15 J. L. Leroy, M. Gueron, J. L. Mergny and C. Helene, *Nucleic Acids Res.*, 1994, **22**, 1600–1606.
- 16 J. Choi, S. Kim, T. Tachikawa, M. Fujitsuka and T. Majima, *J. Am. Chem. Soc.*, 2011, **133**, 16146–16153.
- 17 L. A. Yatsunyk, O. Mendoza and J. L. Mergny, *Acc. Chem. Res.*, 2014, **47**, 1836–1844.
- 18 Z. G. Wang, J. Elbaz and I. Willner, *Nano Lett.*, 2011, **11**, 304–309.
- 19 T. Li and M. Famulok, *J. Am. Chem. Soc.*, 2013, **135**, 1593–1599.
- 20 S. Modi, M. G. Swetha, D. Goswami, G. D. Gupta, S. Mayor and Y. Krishnan, *Nat. Nanotechnol.*, 2009, **4**, 325–330.
- 21 H. Abou Assi, M. Garavis, C. Gonzalez and M. J. Damha, *Nucleic Acids Res.*, 2018, **46**, 8038–8056.
- 22 H. A. Day, P. Pavlou and Z. A. E. Waller, *Bioorg. Med. Chem.*, 2014, **22**, 4407–4418.
- 23 M. Debnath, K. Fatma and J. Dash, *Angew. Chem., Int. Ed.*, 2019, **58**, 2942–2957.
- 24 S. Neidle, *J. Med. Chem.*, 2016, **59**, 5987–6011.
- 25 R. Hansel-Hertsch, M. Di Antonio and S. Balasubramanian, *Nat. Rev. Mol. Cell Biol.*, 2017, **18**, 279–284.
- 26 S. Asamitsu, T. Bando and H. Sugiyama, *Chem.–Eur. J.*, 2019, **25**, 417–430.
- 27 O. Y. Fedoroff, A. Rangan, V. V. Chemeris and L. H. Hurley, *Biochemistry*, 2000, **39**, 15083–15090.
- 28 L. H. Wang, Y. B. Wu, T. G. Chen and C. Y. Wei, *Int. J. Biol. Macromol.*, 2013, **52**, 1–8.
- 29 L. A. Xue, N. Ranjan and D. P. Arya, *Biochemistry*, 2011, **50**, 2838–2849.
- 30 D. L. Ma, M. H. T. Kwan, D. S. H. Chan, P. Lee, H. Yang, V. P. Y. Ma, L. P. Bai, Z. H. Jiang and C. H. Leung, *Analyst*, 2011, **136**, 2692–2696.
- 31 R. R. Gao, S. Shi, Y. Zhu, H. L. Huang and T. M. Yao, *Chem. Sci.*, 2016, **7**, 1853–1861.
- 32 I. J. Lee, S. P. Patil, K. Fhayli, S. Alsaiari and N. M. Khashab, *Chem. Commun.*, 2015, **51**, 3747–3749.
- 33 L. J. Xu, S. N. Hong, N. Sun, K. W. Wang, L. Zhou, L. Y. Ji and R. J. Pei, *Chem. Commun.*, 2016, **52**, 179–182.
- 34 E. P. Wright, H. A. Day, A. M. Ibrahim, J. Kumar, L. J. E. Boswell, C. Huguin, C. E. M. Stevenson, K. Pors and Z. A. E. Waller, *Sci. Rep.*, 2016, **6**, 39456.
- 35 M. Debnath, S. Ghosh, A. Chauhan, R. Paul, K. Bhattacharyya and J. Dash, *Chem. Sci.*, 2017, **8**, 7448–7456.
- 36 B. Shu, J. J. Cao, G. T. Kuang, J. Qiu, M. L. Zhang, Y. Zhang, M. X. Wang, X. Y. Li, S. S. Kang, T. M. Ou, J. H. Tan, Z. S. Huang and D. Li, *Chem. Commun.*, 2018, **54**, 2036–2039.
- 37 S. Dzatko, M. Krafcikova, R. Hansel-Hertsch, T. Fessl, R. Fiala, T. Loja, D. Krafcik, J. L. Mergny, S. Foldynova-Trantirkova and L. Trantirek, *Angew. Chem., Int. Ed.*, 2018, **57**, 2165–2169.
- 38 M. Zeraati, D. B. Langley, P. Schofield, A. L. Moye, R. Rouet, W. E. Hughes, T. M. Bryan, M. E. Dinger and D. Christ, *Nat. Chem.*, 2018, **10**, 631–637.
- 39 R. Manetsch, A. Krasinski, Z. Radic, J. Raushel, P. Taylor, K. B. Sharpless and H. C. Kolb, *J. Am. Chem. Soc.*, 2004, **126**, 12809–12818.
- 40 B. Farrow, M. Wong, J. Malette, B. Lai, K. M. Deyle, S. Das, A. Nag, H. D. Agnew and J. R. Heath, *Angew. Chem., Int. Ed.*, 2015, **54**, 7114–7119.
- 41 I. Glassford, C. N. Teijaro, S. S. Daher, A. Weil, M. C. Small, S. K. Redhu, D. J. Colussi, M. A. Jacobson, W. E. Childers, B. Buttarro, A. W. Nicholson, A. D. MacKerell, B. S. Cooperman and R. B. Andrade, *J. Am. Chem. Soc.*, 2016, **138**, 3136–3144.
- 42 H. D. Agnew, R. D. Rohde, S. W. Millward, A. Nag, W. S. Yeo, J. E. Hein, S. M. Pitram, A. A. Tariq, V. M. Burns, R. J. Krom, V. V. Fokin, K. B. Sharpless and J. R. Heath, *Angew. Chem., Int. Ed.*, 2009, **48**, 4944–4948.
- 43 A. T. Poulin-Kerstien and P. B. Dervan, *J. Am. Chem. Soc.*, 2003, **125**, 15811–15821.
- 44 M. Di Antonio, G. Biffi, A. Mariani, E. A. Raiber, R. Rodriguez and S. Balasubramanian, *Angew. Chem., Int. Ed.*, 2012, **51**, 11073–11078.
- 45 D. Panda, P. Saha, T. Das and J. Dash, *Nat. Commun.*, 2017, **8**, 16103.
- 46 S. G. Rzuczek, H. Park and M. D. Disney, *Angew. Chem., Int. Ed.*, 2014, **53**, 10956–10959.
- 47 S. E. Kim, I. B. Lee, C. Hyeon and S. C. Hong, *J. Phys. Chem. B*, 2014, **118**, 4753–4760.
- 48 J. L. Mergny, *Biochemistry*, 1999, **38**, 1573–1581.



- 49 A. De Cian, L. Guittat, M. Kaiser, B. Sacca, S. Amrane, A. Bourdoncle, P. Alberti, M. P. Teulade-Fichou, L. Lacroix and J. L. Mergny, *Methods*, 2007, **42**, 183–195.
- 50 I. Bessi, C. Bazzicalupi, C. Richter, H. R. A. Jonker, K. Saxena, C. Sissi, M. Chioccioli, S. Bianco, A. R. Bilia, H. Schwalbe and P. Gratteri, *ACS Chem. Biol.*, 2012, **7**, 1109–1119.
- 51 M.-P. Teulade-Fichou, C. Carrasco, L. Guittat, C. Bailly, P. Alberti, J.-L. Mergny, A. David, J.-M. Lehn and W. D. Wilson, *J. Am. Chem. Soc.*, 2003, **125**, 4732–4740.
- 52 V. Kumar, A. Sengupta, K. Gavvala, R. K. Koninti and P. Hazra, *J. Phys. Chem. B*, 2014, **118**, 11090–11099.
- 53 J. Alzeer and N. W. Luedtke, *Biochemistry*, 2010, **49**, 4339–4348.
- 54 V. Dhamodharan and P. I. Pradeepkumar, *ACS Chem. Biol.*, 2019, **14**, 2102–2114.
- 55 D. Panda, P. Saha, R. Chaudhuri, T. Prasanth, V. Ravichandiran and J. Dash, *Anal. Chem.*, 2019, **91**, 7705–7711.

